Helius Story

<div class='circular--portrait' style='background:#82ADFD;color: #ffffff;font-size:4em;'>HM</div>
HSDT -- USA Stock  

USD 16.30  0.60  3.55%

Helius Medical Return on Invested Capital is comparatively stable at the moment as compared to the past year. Helius Medical reported Return on Invested Capital of 7.53 in 2020. Tangible Assets Book Value per Share is likely to gain to 0.42 in 2021, whereas Earnings before Tax are likely to drop (9.5 M) in 2021. The rationale behind this perspective is to forecast a future value of Helius Medical using technical analysis. What exactly are Helius Medical private investors should expect in February?
Published over two weeks ago
View all stories for Helius Medical | View All Stories
Are Helius (NASDAQ:HSDT) private investors starting to hold back?
Helius Medical is FAIRLY VALUED at 0.36 per share with modest projections ahead. About 18.0% of Helius Medical shares are held by company insiders. Insiders ownership of Helius Medical Techn refers to the amount of Helius Medical Techn equity owned by Helius officers, directors, relatives of the leadership team, or anyone who has access to private information before it's made available to the public. Check out our latest analysis of Helius, including its current ownership diagnostics.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Helius Medical Techn. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Helius Medical

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Helius Medical's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Helius Medical in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Helius Medical. Your research has to be compared to or analyzed against Helius Medical's peers to derive any actionable benefits. When done correctly, Helius Medical's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Helius Medical Techn.

How important is Helius Medical's Liquidity

Helius Medical financial leverage refers to using borrowed capital as a funding source to finance Helius Medical ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Helius Medical financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Helius Medical's total debt and its cash.

How Helius utilizes its cash?

To perform a cash flow analysis of Helius Medical, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Helius Medical is receiving and how much cash it distributes out in a given period. The Helius Medical cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Helius Medical Net Cash Flow from Operations is comparatively stable at the moment as compared to the past year. Helius Medical reported Net Cash Flow from Operations of (18.9 Million) in 2020

Detailed Outlook On Helius Medical

The newest price gain of Helius Medical may raise some interest from private investors. The stock closed today at a share price of 18.35 on 2,375,400 in trading volume. The company executives may have good odds in positioning the firm resources to exploit market volatility in February. The stock standard deviation of daily returns for 30 days investing horizon is currently 128.23. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Helius Medical partners.

Margin Breakdown

EBITDA Margin(7.95)
Gross Margin0.51
Profit Margin(8.11)

Can Helius Medical build up on the newest gain?

Newest sortino ratio is at 8.68. Helius Medical is displaying above-average volatility over the selected time horizon. Investors should scrutinize Helius Medical independently to ensure intended market timing strategies are aligned with expectations about Helius Medical volatility.

The Current Takeaway on Helius Medical Investment

Whereas some firms under the medical devices industry are still a bit expensive, Helius Medical may offer a potential longer-term growth to private investors. The inconsistency in the assessment between current Helius valuation and our trade advice on Helius Medical is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Helius Medical.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Helius Medical. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com